Evidence map›Paper›PMID 27741241›Full record

ArticlePLoS neglected tropical diseases2016

Noninvasive Diagnosis of Visceral Leishmaniasis: Development and Evaluation of Two Urine-Based Immunoassays for Detection of Leishmania donovani Infection in India.

Sarfaraz Ahmad Ejazi, Pradyot Bhattacharya, Md Asjad Karim Bakhteyar, Aquil Ahmad Mumtaz, Krishna Pandey, Vidya Nand Ravi Das, Pradeep Das, Mehebubar Rahaman, Rama Prosad Goswami, Nahid Ali

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Development of Immunological Assays Based onFrontiers in cellular and infection microbiology · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Molecular Tracking of theFrontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Sarfaraz Ahmad EjaziInfectious Diseases and Immunology Division, Indian Institute of Chemical Biology, Kolkata, India.
Pradyot BhattacharyaInfectious Diseases and Immunology Division, Indian Institute of Chemical Biology, Kolkata, India.
Md Asjad Karim BakhteyarDepartment of Medicine, Shri Krishna Medical College and Hospital, Muzaffarpur, India.
Aquil Ahmad MumtazDepartment of Medicine, Shri Krishna Medical College and Hospital, Muzaffarpur, India.
Krishna PandeyDepartment of Clinical Medicine, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Vidya Nand Ravi DasDepartment of Clinical Medicine, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Pradeep DasDepartment of Molecular Biology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Mehebubar RahamanDepartment of Tropical Medicine, School of Tropical Medicine, Kolkata, India.
Rama Prosad GoswamiDepartment of Tropical Medicine, School of Tropical Medicine, Kolkata, India.
Nahid AliInfectious Diseases and Immunology Division, Indian Institute of Chemical Biology, Kolkata, India.
Indian Institute of Chemical Biology · INRajendra Memorial Research Institute of Medical Sciences · INIndian Institute of Tropical Meteorology · INShree Krishna Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVisceral Leishmaniasis (VL), a severe parasitic disease, could be fatal if diagnosis and treatment is delayed. Post kala-azar dermal leishmaniasis (PKDL), a skin related outcome, is a potential reservoir for the spread of VL. Diagnostic tests available for VL such as tissue aspiration are invasive and painful although they are capable of evaluating the treatment response. Serological tests although less invasive than tissue aspiration are incompetent to assess cure. Parasitological examination of slit-skin smear along with the clinical symptoms is routinely used for diagnosis of PKDL. Therefore, a noninvasive test with acceptable sensitivity and competency, additionally, to decide cure would be an asset in disease management and control. METHODOLOGY/PRINCIPAL

findingsWe describe here, the development of antibody-capture ELISA and field adaptable dipstick test as noninvasive diagnostic tools for VL and PKDL and as a test of cure in VL treatment. Sensitivity and specificity of urine-ELISA were 97.94% (95/97) and 100% (75/75) respectively, for VL. Importantly, dipstick test demonstrated 100% sensitivity (97/97) and specificity (75/75) in VL diagnosis. Degree of agreement of the two methods with tissue aspiration was 98.83% (κ = 0.97) and 100% (κ = 1), for ELISA and dipstick test, respectively. Both the tests had 100% positivity for PKDL (14/14) cases. ELISA and dipstick test illustrated treatment efficacy in about 90% (16/18) VL cases when eventually turned negative after six months of treatment. CONCLUSIONS/SIGNIFICANCE: ELISA and dipstick test found immensely effective for diagnosis of VL and PKDL through urine samples thus, may substitute the existing invasive diagnostics. Utility of these tests as indirect methods of monitoring parasite clearance can define infected versus cured. Urine-based dipstick test is simple, sensitive and above all noninvasive method that may help not only in active VL case detection but also to ascertain treatment response. It can therefore, be deployed widely for interventions in disease management of VL particularly in poor resource outskirts.

Indexed as

Antibodies, ProtozoanEnzyme-Linked Immunosorbent AssayHumansIndiaLeishmania donovaniLeishmaniasis, CutaneousLeishmaniasis, VisceralAntibodies, Protozoan

Identifiers

PMID27741241
PMCPMC5065134
OpenAlexW2530568360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.